A5102820912- Glioma Diagnosis and Treatment
- Chromatin Remodeling and Cancer
- Radiomics and Machine Learning in Medical Imaging
- MicroRNA in disease regulation
- Mechanisms of cancer metastasis
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Mechanisms and Therapy
- Circular RNAs in diseases
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Cancer-related molecular mechanisms research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Histone Deacetylase Inhibitors Research
- PARP inhibition in cancer therapy
- Galectins and Cancer Biology
- Cancer, Lipids, and Metabolism
- Advanced Radiotherapy Techniques
- Head and Neck Cancer Studies
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- RNA regulation and disease
- Meningioma and schwannoma management
- RNA modifications and cancer
The Ohio State University
2016-2025
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2009-2024
The Ohio State University Wexner Medical Center
2010-2023
Shree Guru Gobind Singh Tricentenary University
2020
Medical University of South Carolina
2019
University of Houston
2019
Massachusetts General Hospital
2001-2016
Columbia University Irving Medical Center
2016
Arizona Oncology
2016
Barrow Neurological Institute
2016
Concurrent treatment with temozolomide and radiotherapy followed by maintenance is the standard of care for patients newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, currently approved recurrent Whether addition bevacizumab would improve survival among glioblastoma not known.
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant treatment response. Dose-dense (DD) results in prolonged depletion MGMT blood mononuclear cells possibly tumor. This trial tested whether DD improves overall survival (OS) or progression-free (PFS) patients GBM. Patients Methods phase III enrolled older than age 18...
Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), vincristine after radiation therapy at the time initial diagnosis resulted longer progression-free survival, but not overall than alone. We now report long-term results.We included patients grade astrocytoma, oligoastrocytoma, or oligodendroglioma who were younger 40 years age had...
Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one lethal all cancers. Epidermal growth factor receptor (EGFR) mutations (EGFRvIII) phosphoinositide 3-kinase (PI3K) hyperactivation are in GBM, promoting survival, including through sterol regulatory element-binding protein 1 (SREBP-1)-dependent lipogenesis. The role cholesterol metabolism GBM pathogenesis, its association with EGFR/PI3K signaling, potential therapeutic targetability unknown. In our...
Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit response to standard therapy. To date, biomarker panel predictive power distinguish treatment sensitive from refractory GBM tumors does not exist. An analysis was performed using microarray data 4 independent sets. examination the genes consistently associated patient outcome, revealed consensus 38-gene survival set. Worse outcome increased expression mesenchymal differentiation and angiogenesis. Application formalin...
NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc sought determine prognostic and predictive impact WHO-defined molecular subgroups corresponding alterations within 9802.IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel...
Given the DNA fingerprints of two individuals with some bands being shared by both individuals, we define a new measure degree similarity between profiles individuals. We use this to calculate expected unrelated randomly mating population; is due chance only. Then, related obtained; andrelatedness. From these results, relatedness alone may be calculated.
Abstract Purpose: In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells. Experimental Design: Using a panel of four primary human cell lines with heterogeneous O6-methylguanine-DNA methyltransferase (MGMT) protein expression, normal astrocytes, and U87 xenografts, (a) relationship MGMT status efficacy temozolomide-based chemoradiation using vitro vivo assays; (b) underlying effect cells; (c) strategies to overcome resistance +...
Abstract Purpose: Poly (ADP-ribose) polymerase (PARP) inhibitors are undergoing clinical evaluation for cancer therapy. Because PARP inhibition has been shown to enhance tumor cell sensitivity radiation, we investigated the in vitro and vivo effects of novel inhibitor E7016. Experimental Design: The effect E7016 on radiosensitivity lines was evaluated using clonogenic survival. DNA damage repair were measured γH2AX foci neutral comet assay. Mitotic catastrophe determined by immunostaining....
Glioblastoma (GBM) is the most common primary malignant brain tumor. Nomograms are often used for individualized estimation of prognosis. This study aimed to build and independently validate a nomogram estimate survival probabilities patients with newly diagnosed GBM, using data from 2 independent NRG Oncology Radiation Therapy Group (RTOG) clinical trials.This analysis included information on 799 (RTOG 0525) 555 0825) eligible randomized GBM contained following variables: age at diagnosis,...
Despite aggressive therapies, median survival for malignant gliomas is less than 15 months. Patients with unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) fare worse, presumably because of temozolomide resistance. AdV-tk, an adenoviral vector containing the herpes simplex virus thymidine kinase gene, plus prodrug synergizes surgery and chemoradiotherapy, kills tumor cells, has not shown MGMT dependency, elicits antitumor vaccine effect.Patients newly diagnosed glioma received...
The initial report of NRG Oncology/Radiation Therapy Oncology Group (RTOG) 0424 demonstrated a 3-year overall survival benefit with the addition temozolomide to radiotherapy compared historical control. However, an important end point trial-evaluation association between O6-methylgaunine-DNA-methyltransferase (MGMT) promoter methylation and outcomes-was not previously reported.To examine proportion patients in Oncology/RTOG MGMT its outcomes.Specimens collected were analyzed after trial...
2006 Background: Radiotherapy with concomitant and adjuvant TMZ (TMZ/RT→TMZ) is the standard of care for newly diagnosed GBM. MGMT methylation status may be an important determinant treatment response. Compared TMZ, dd results in prolonged depletion blood mononuclear cells possibly tumor. This trial determined if intensified improves survival (OS) or progression free (PFS). Methods: phase III was conducted by RTOG, EORTC NCCTG. Neurologically stable patients adequate tissue prospective...
We conducted genome-wide miRNA-sequencing (miRNA-seq) in primary cancer tissue from patients of lung adenocarcinoma to identify markers for the presence lymph node metastasis.Markers metastasis identified by sequencing were validated a separate cohort using quantitative PCR. After additional validation The Cancer Genome Atlas (TCGA) dataset, functional characterization studies vitro.MiR-31 was upregulated tissues with metastases compared those without metastases. confirmed miR-31 be...
We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma head and neck (SCCHN).Patients with chemotherapy-naïve (or prior platinum as part multimodal therapy completed ≥ 4 months earlier) SCCHN were randomly assigned receive doublet without bevacizumab 15 mg/kg given intravenously every 3 weeks until disease progression. Chemotherapy could be...
PURPOSE Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk METHODS Patients had cell carcinoma of the (SCCHN) oral cavity, oropharynx, or larynx, with one more risk factors warranting postoperative RT. were randomly assigned 1:1 to intensity-modulated (60-66 Gy) once-per-week C alone. The primary hypothesis was that + would improve overall survival (OS)...